Arvinas, Inc.
General ticker "ARVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $683.6M (TTM average)
Arvinas, Inc. does not follow the US Stock Market performance with the rate: -24.4%.
Estimated limits based on current volatility of 3.4%: low 6.83$, high 7.32$
Factors to consider:
- Total employees count: 246 (-42.8%) as of 2025
- Top business risk factors: Failure to achieve profitability, Clinical trial failure, Regulatory and compliance, Intellectual property risks, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.06$, 17.62$]
- 2026-12-31 to 2027-12-31 estimated range: [6.72$, 16.67$]
Financial Metrics affecting the ARVN estimates:
- Positive: with PPE of -9.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of 52.14 > 2.08
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ARVN quotes
Long-term ARVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $78.50MM | $263.40MM | $262.60MM |
| Operating Expenses | $480.00MM | $513.60MM | $381.10MM |
| Operating Income | $-401.50MM | $-250.20MM | $-118.50MM |
| Non-Operating Income | $37.60MM | $51.90MM | $38.00MM |
| R&D Expense | $379.70MM | $348.20MM | $285.20MM |
| Income(Loss) | $-363.90MM | $-198.30MM | $-80.50MM |
| Taxes | $0.90MM | $0.60MM | $0.30MM |
| Other Income(Loss) | $-2.50MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-364.80MM | $-198.90MM | $-80.80MM |
| Stockholders Equity | $660.00MM | $561.70MM | $433.90MM |
| Assets | $1,304.60MM | $1,091.40MM | $717.90MM |
| Operating Cash Flow | $-347.80MM | $-259.30MM | $-273.80MM |
| Capital expenditure | $2.90MM | $1.80MM | $1.90MM |
| Investing Cash Flow | $203.50MM | $34.70MM | $407.60MM |
| Financing Cash Flow | $374.70MM | $7.90MM | $-91.40MM |
| Earnings Per Share** | $-6.57 | $-2.77 | $-1.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.